designed three types of CAR-T cells in order to simultaneously target PSMA expressing cells and capture local soluble IL-23 produced by tumor cells or by MDSCs: either (i) dual or duo CAR-Ts expressing 2 CARs at the surface (IL-23mAb-T2A-PSMA), or (ii) a tandem CAR IL-23mAb/PSMA or (iii) PSMA-CARs secreting anti-Il-23 Ab. The gene discussed is FOLH1; the disease is neoplasm.